Evidence map›Paper›PMID 38819641›Full record

ArticleCancer research2024

Human 3D Ovarian Cancer Models Reveal Malignant Cell-Intrinsic and -Extrinsic Factors That Influence CAR T-cell Activity.

Joash D Joy, Beatrice Malacrida, Florian Laforêts, Panoraia Kotantaki, Eleni Maniati, Ranjit Manchanda, Alessandro Annibaldi, Sarah Hopkins, Ianire Garrobo-Calleja, Julien Gautrot and 1 more

Abstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. CD8Frontiers in immunology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Joash D JoyBarts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-5700-2582
Beatrice MalacridaBarts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-6977-4141
Florian LaforêtsBarts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-0924-5691
Panoraia KotantakiBarts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0003-1098-9994
Eleni ManiatiBarts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-6993-9890
Ranjit ManchandaWolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, London, United Kingdom.ORCID 0000-0003-3381-5057
Alessandro AnnibaldiCentre for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-0346-4340
Sarah HopkinsGlaxoSmithKline Medicines Research Centre, Stevenage, United Kingdom.ORCID 0009-0006-7475-3277
Ianire Garrobo-CallejaGlaxoSmithKline Medicines Research Centre, Stevenage, United Kingdom.ORCID 0009-0006-5246-9398
Julien GautrotSchool of Engineering and Material Science, Centre for Bioengineering, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-1614-2578
Frances R BalkwillBarts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-5587-9759

Funding

Barts Charity ECMG1B6RBiotechnology and Biological Sciences Research Council (BBSRC) BIDS3000032485Cancer Research UK (CRUK) C16420/A18066Cancer Research UK (CRUK) C587/A16354Ovarian Cancer Research Alliance (OCRA) 648516UKRI EP/X028704/1
6 · The paper itself

Abstract

In vitro preclinical testing of chimeric antigen receptor (CAR) T cells is mostly carried out in monolayer cell cultures. However, alternative strategies are needed to take into account the complexity and the effects of the tumor microenvironment. Here, we describe the modulation of CAR T-cell activity by malignant cells and fibroblasts in human three-dimensional (3D) in vitro cell models of increasing complexity. In models combining mucin-1 (MUC1) and TnMUC1 CAR T cells with human high-grade serous ovarian cancer cell spheroids, malignant cell-intrinsic resistance to CAR T-cell killing was due to defective death receptor signaling involving TNFα. Adding primary human fibroblasts to spheroids unexpectedly increased the ability of CAR T cells to kill resistant malignant cells as CCL2 produced by fibroblasts activated CCR2/4+ CAR T cells. However, culturing malignant cells and fibroblasts in collagen gels engendered production of a dense extracellular matrix that impeded CAR T-cell activity in a TGFβ-dependent manner. A vascularized microfluidic device was developed that allowed CAR T cells to flow through the vessels and penetrate the gels in a more physiological way, killing malignant cells in a TNFα-dependent manner. Complex 3D human cell models may provide an efficient way of screening multiple cytotoxic human immune cell constructs while also enabling evaluation of mechanisms of resistance involving cell-cell and cell-matrix interactions, thus accelerating preclinical research on cytotoxic immune cell therapies in solid tumors. Significance: Three-dimensional in vitro models of increasing complexity uncover mechanisms of resistance to CAR T cells in solid tumors, which could help accelerate development of improved CAR T-cell constructs.

Indexed as

Immunotherapy, AdoptiveOvarian NeoplasmsReceptors, Chimeric AntigenSpheroids, CellularT-LymphocytesTumor MicroenvironmentCell Line, TumorFemaleFibroblastsHumansReceptors, Chimeric Antigen

Identifiers

PMID38819641
PMCPMC11292204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.